Congo Opens First Pivotal Trial for a Bundibugyo Ebola Vaccine
DR CONGO — October 24, 2026
Congolese researchers vaccinated the first participant in a pivotal trial aimed at closing one of the deadliest gaps in global health: there is still no approved vaccine against Bundibugyo Ebola.
The TUMAINI trial opened in Bunia on October 23 as the Democratic Republic of the Congo fights the largest recorded outbreak of the Bundibugyo virus. The Coalition for Epidemic Preparedness Innovations said the country had confirmed 9,552 cases and 4,602 deaths by October 21. The World Health Organization confirmed the launch and described the study as a pivotal Phase 2/3 trial designed to establish whether candidate vaccines can safely and effectively protect people.
This is not a ceremonial launch. It is a race to turn scientific capacity into public protection while families, health workers and entire communities are living through an emergency.
A TUMAINI trial participant speaks with health workers in Bunia, Democratic Republic of the Congo, on October 23, 2026. Photo: CEPI / TUMAINI trial. Source.
A trial built inside the emergency response
TUMAINI—“hope” in Swahili—is an adaptive platform trial. That design allows researchers to evaluate several vaccine candidates inside one framework instead of building a separate study for each product. It can save time during an outbreak without abandoning the evidence required for a licensed vaccine.
The first candidate is Ervebo, a vaccine already licensed against the more common Zaire Ebola virus but not against Bundibugyo. The trial will test whether it can protect people exposed to this different virus. CEPI said candidates developed specifically for Bundibugyo by Moderna and by the University of Oxford with the Serum Institute of India are being prepared to enter the platform.
Researchers will use ring vaccination, enrolling contacts at high risk of infection around confirmed cases. The trial includes pregnant women and children aged 12 and older; children from one year of age can receive Ervebo. Those groups have too often been excluded from clinical research even when outbreaks hit them hardest.
The study is led and co-sponsored by Congo’s National Institute of Biomedical Research and the University of Antwerp, with national oversight from the Congolese Health Ministry. WHO, Africa CDC, Médecins Sans Frontières, the Institute of Tropical Medicine Antwerp and other partners are supporting implementation. Congolese scientific leadership is not a footnote here. It is the backbone of the trial.
Public science must produce public access
The outbreak’s scale makes the research urgent. Bundibugyo Ebola has moved beyond Congo: Kenya announced a second death on October 23, while Nigerian authorities are investigating the route behind their first confirmed case. Kenyan officials traced 135 contacts connected to the country’s first patient, and eight people tested positive while already in quarantine.
An epidemic does not respect borders, but the tools to fight it remain distributed through borders of wealth, patents and manufacturing power. Earlier this year, Gavi committed up to $40 million to prepare manufacturing so successful vaccines can be produced at scale. That investment must translate into affordable doses, regional stockpiles and delivery systems controlled by public-health need—not scarcity pricing.
Archive: A health worker vaccinates a woman during an Ebola campaign in Bulape, Democratic Republic of the Congo, in 2025. Photo: WHO Regional Office for Africa. Source.
The trial also demands trust. Researchers are asking people facing a lethal disease to participate in a study during an emergency. That trust cannot be imposed by foreign institutions or bought with a press release. It must be built through informed consent, transparent results, reliable care and the visible leadership of Congolese health workers and communities.
If TUMAINI succeeds, it will not erase the failures that allowed the outbreak to spread. It could, however, change the next chapter: a licensed tool against a virus that has killed thousands, tested under African leadership and built around the communities carrying the heaviest burden.
Hope, in this case, is not passive. It is organized science—and a demand that the protection it produces belongs to everyone.
Sources
CEPI — First participant vaccinated in pivotal Phase 2/3 Bundibugyo vaccine trial (October 23, 2026)
Image provenance: Lead image shows a TUMAINI trial participant with health workers in Bunia on October 23, 2026, supplied by CEPI. The V9 cover uses a crop without altering the photograph’s geometry.
Comments